New research, co-funded by Cystic Fibrosis Trust, has uncovered evidence that might explain why long-term infections, which are commonly experienced by people with cystic fibrosis (CF), are so difficult to treat.
Last month we surpassed a monumental milestone – with over 1,000 people with cystic fibrosis being recruited to a clinical trial since the Trials Accelerator launched
The UK Cystic Fibrosis Clinical Trials Conference recently took place in Nottingham, bringing together researchers and clinicians from across the country to hear about the changing landscape of CF clinical trials.
As part of our #CFTruths campaign, 6-year-old Henry, who lives with CF, and his sister Emma, 9, share some of the things they wish more people knew about cystic fibrosis. What are your #CFTruths? Follow us on social media @cftrustuk and join the conversation!
Cystic fibrosis (CF) is often described as an invisible illness: despite the battles going on inside the body, a person with CF might not always look ‘ill’ on the outside. Here, we take a look at just some of the invisible symptoms of CF…
To improve medical care, it is important to collect information about the quality of life of people who receive medicines and also that of their parents. Vertex Pharmaceuticals Inc., the company who developed Orkambi and Symkevi for the treatment of Cystic Fibrosis, is conducting this observational study at hospitals in the UK to collect additional information on the quality of life of 6-11 year olds receiving these medicines and that of their parents. For those who are eligible to participate, after signing the data consent form, participants’ medical records relating to the history of their CF disease, including current and...
The main aim of the study is to assess safety and effectiveness of the CFTR modulator combination therapy Galicaftor/Navocaftor/ABBV-119 in adult participants with CF who are homozygous or heterozygous for the F508del mutation in each arm. Galicaftor/Navocaftor/ABBV-119 combination therapy is an investigational therapy for the treatment of CF. Galicaftor (CFTR corrector), Navocaftor (CFTR potentiator) and ABBV-119 (CFTR corrector) are CFTR modulators which aim to help the faulty CFTR protein to function properly. Study doctors place participants into 1 of 4 treatment groups, called treatment arms. Each group receives a different treatment regime. Around 90 adult participants with a diagnosis of...
